Perspective Therapeutics, Inc. (CATX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Johan M. Spoor | CEO & Director | 948.22k | -- | 1972 |
| Mr. Jonathan R. Hunt | Chief Accounting Officer | 611.16k | -- | 1967 |
| Dr. Markus Puhlmann M.B.A., M.D. | Chief Medical Officer | 702.24k | -- | 1966 |
| Mr. Juan Graham | Chief Financial Officer | -- | -- | 1977 |
| Mr. Shane Cobb | Executive Vice President of Operations | -- | -- | -- |
| Dr. Michael K. Schultz Ph.D. | Chief Science Officer | -- | -- | -- |
| Ms. Annie J. Cheng | Vice President of Investor Relations | -- | -- | 1976 |
| Mr. Chris Nenno | General Counsel & Corporate Secretary | -- | -- | -- |
| Mr. Andrew Bright | Executive Vice President of Brachytherapy | -- | -- | -- |
| Mr. Amos Hedt BA, PGradDip | Chief Business Strategy Officer | -- | -- | -- |
Perspective Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Medical Devices
- Full Time Employees:
- 138
Description
Perspective Therapeutics, Inc., together with its subsidiaries, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. The company discovers, and develop its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha; and PSV4XX, a differentiated prostate-specific membrane antigen-targeted alpha therapy. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.
Corporate Governance
Upcoming Events
May 12, 2025 at 8:36 PM UTC
Perspective Therapeutics, Inc. Earnings Date
Recent Events
May 19, 2025 at 12:00 AM UTC
SD: Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
April 4, 2025 at 12:00 AM UTC
POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing